Who owns Dyne Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of DYN from SEC Form 13F filings across 244 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 244 institutions disclosed 190.4M shares of Dyne Therapeutics, Inc. worth $4.23B — about 115.1% of shares outstanding; the largest disclosed holder is T. Rowe Price Investment Management, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
244
13F holders
$4.23B
value, 2026 filers
115.1%
of shares outstanding (190.4M sh)
50
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of DYN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 30.9M | $686.6M | 0.5% | 18.7% | +0.4% |
| 2 | BlackRock, Inc. | 12.4M | $275.5M | 0.0% | 7.5% | +6.0% |
| 3 | Jupiter Topco LLCNEW | 12.0M | $266.6M | 0.1% | 7.3% | new |
| 4 | FMR LLC | 11.2M | $248.9M | 0.0% | 6.8% | +25.8% |
| 5 | STATE STREET CORP | 7.5M | $165.6M | 0.0% | 4.5% | +12.1% |
| 6 | Orbis Allan Gray Ltd | 7.0M | $155.6M | 0.5% | 4.2% | +3.6% |
| 7 | Atlas Venture Life Science Advisors, LLC | 6.8M | $151.0M | 17.1% | 4.1% | -25.5% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 6.3M | $140.2M | 0.0% | 3.8% | -1.5% |
| 9 | TCG Crossover Management, LLC | 4.6M | $102.5M | 2.5% | 2.8% | 0.0% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.0M | $89.9M | 0.0% | 2.4% | -2.7% |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.9M | $87.4M | 0.0% | 2.4% | +69.1% |
| 12 | FCPM III SERVICES B.V. | 3.8M | $85.5M | 11.4% | 2.3% | -17.1% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 3.7M | $83.2M | 0.0% | 2.3% | +6.8% |
| 14 | Vestal Point Capital, LP | 3.4M | $75.0M | 1.8% | 2% | -15.6% |
| 15 | ORBIMED ADVISORS LLC | 3.2M | $71.9M | 1.3% | 2% | +10.9% |
| 16 | Frazier Life Sciences Management, L.P. | 3.2M | $70.0M | 1.5% | 1.9% | 0.0% |
| 17 | JPMORGAN CHASE & CO | 3.2M | $67.2M | 0.0% | 1.9% | -3.1% |
| 18 | ARMISTICE CAPITAL, LLC | 3.1M | $68.6M | 0.8% | 1.9% | -2.8% |
| 19 | PERCEPTIVE ADVISORS LLC | 2.7M | $59.7M | 0.9% | 1.6% | -42.4% |
| 20 | Logos Global Management LP | 2.5M | $56.6M | 2.4% | 1.5% | +82.1% |
| 21 | BANK OF AMERICA CORP /DE/ | 2.2M | $49.6M | 0.0% | 1.3% | +54.7% |
| 22 | Venrock Adviser, LLC | 2.2M | $48.3M | 1.5% | 1.3% | 0.0% |
| 23 | GOLDMAN SACHS GROUP INC | 2.2M | $47.9M | 0.0% | 1.3% | +25.2% |
| 24 | Siren, L.L.C. | 2.1M | $47.3M | 1.0% | 1.3% | -4.5% |
| 25 | FRANKLIN RESOURCES INC | 2.0M | $45.1M | 0.0% | 1.2% | +1.1% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.